SCHEMBL23054872

SCHEMBL23054872

CCCSc1nc2cc(S(=O)(=O)Nc3ccc(C(=O)NO)cc3)ccc2s1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.47
HDAC6 Q9UBN7 6/20 0.46
HDAC3 O15379 2/20 0.46
HDAC11 Q96DB2 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
LDHA P00338 2/20 0.45
PPARA Q07869 4/20 0.44
ALOX5 P09917 1/20 0.43
POLB P06746 2/20 0.42
ALDH1A1 P00352 1/20 0.42
GFER P55789 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 5/20 0.42
KDM4E B2RXH2 1/20 0.42
RECQL P46063 1/20 0.42
PPARG P37231 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
PPARD Q03181 1/20 0.41
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480564 0.87 MAPT (0.51) TRPV1HDAC6HDAC3HDAC11HDAC8
SCHEMBL15482249 0.84 HDAC6 (0.47) TRPV1HDAC6HDAC3HDAC11HDAC8
SCHEMBL23054931 0.83 ALOX5 (0.44) HDAC6LDHAALOX5ALDH1A1GFER
SCHEMBL15480586 0.81 ALDH1A1 (0.60) TRPV1HDAC6HDAC3HDAC11HDAC8
SCHEMBL15480582 0.79 HDAC6 (0.50) TRPV1HDAC6HDAC3HDAC11HDAC8
SCHEMBL15480583 0.79 HDAC6 (0.50) TRPV1HDAC6HDAC3HDAC11HDAC8
SCHEMBL15480570 0.72 HDAC8 (0.49) HDAC6HDAC3HDAC11HDAC8POLB
SCHEMBL18407539 0.71 KMT2A (0.53) HDAC6HDAC3HDAC11HDAC8POLB
SCHEMBL15480626 0.69 CYP1A2 (0.46) HDAC6HDAC3HDAC8POLBALDH1A1
SCHEMBL15480578 0.69 HDAC8 (0.48) HDAC6HDAC3HDAC11HDAC8POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB (SE) 2021-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210060014-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 TRPV1 3116/4885HDAC6 10/4885HDAC3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.